Home » Newsletters » BioWorld Science

BioWorld Science

Nov. 23, 1999

View Archived Issues

Adolor updates product pipeline at BIO Europe '99

Company Profile: FeRx

Myriad Genetics identifies new HIV drug target

OSI Pharmaceuticals updates oncology programs with Pfizer

Achievements at Genta during third quarter

Novel indolyl derivatives useful for schizophrenia and related disorders

Solid-phase synthesis and use of novel inhibitors of aspartyl proteases reported by Pharmacopeia

U.K. launch of Meningitec coincides with initiation of national immunization program

Dopamine D4 ligands, their preparation and use in schizophrenia and related disorders

CA4P activity reviewed at AACR-NCI-EORTC meeting; Oxigene signs letter of intent with BMS

Tanox patents G-CSF receptor agonists, including MAbs, and their use

Pfizer's portfolio includes new early-stage compounds for MED

NY-ESO-1-derived peptides and their use in cancer therapy and diagnosis

NeXstar presents aptamer against tenascin-C with potential for cancer imaging and therapy

LY-315920 examined for pharmacokinetics following continuous infusion in volunteers

Food reduces rate (but not exent) of absorption of LU-135252/HMR-4005 in man

North American Vaccine to be acquired by Baxter

Novel prostate cancer therapy in development at Procyon detailed at international conference

Preclinical profile of tyrosine kinase inhibitor supports initiation of clinical testing

Pharma Mar isolates marine compound with potent and selective activity against solid tumors

FTY-720: population pharmacokinetics analyzed in transplant patients

Diatide's radiolabeled somatostatin analogue exerts potent antitumor effects in mice

Patent for paclitaxel formulations issued to NaPro BioTherapeutics

Agouron initiates pilot phase II trial of prinomastat as treatment of glioblastoma multiforme

AAPS news: clinical pharmacokinetic analysis of B43-genistein in patients

NeoTherapeutics forms subsidiary to develop drugs discovered through collaboration with UC Irvine

New SERM from SRI and Taiho holds excellent clinical potential

Pharmacokinetics of novel anti-HIV immunoconjugate in nonhuman primates and patients

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 9, 2026.
Cas and effect: Merck’s phase III ripples HIF-2α space
BioWorld
Oddsmakers wasted no time figuring the market chances after Merck & Co. Inc. rolled out data from the phase III Litespark-011 study testing its oral...
Brain’s hidden tau-clearing pathway uncovered
BioWorld Science
Researchers at INSERM and collaborators have identified hypothalamic tanycytes as mediators of tau clearance and shown that their structural and genetic...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 10, 2026
MSD synthesizes α-synuclein PET agents
BioWorld Science
Merck Sharp & Dohme LLC (MSD) has prepared and tested new positron emission tomography (PET) agents for binding and imaging α-synuclein (SNCA) for the diagnosis...